Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design.
This setback removes a late-stage cardiovascular candidate from Ionis’ pipeline spotlight and shifts attention toward earlier-stage RNA-targeted programs such as ION337 for Dravet syndrome.
We’ll now examine how the Phase 3 eplontersen trial failure and resulting scrutiny could reshape Ionis Pharmaceuticals’ long-term investment narrative.
Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
What Is Ionis Pharmaceuticals’ Investment Narrative?
For Ionis, the core investment case still hinges on its RNA-targeted platform translating into multiple commercial drugs that can eventually support profitability, not on any single asset. The surprise failure of eplontersen in ATTR-CM clearly dents that story in the near term, as reflected in the roughly 23% share price drop and a reset of expectations around late-stage cardiovascular upside. At the same time, the broader catalyst map has shifted rather than disappeared: recently approved products like TRYNGOLZA and DAWNZERA, upcoming PDUFA decisions for zilganersen and bepirovirsen, and early programs such as Fast Track–designated ION337 now matter more in sustaining the growth narrative implied by prior revenue and earnings forecasts. The biggest risks are that high R&D spend and trial setbacks continue to delay profitability and invite further scrutiny of management’s execution.
However, Ionis’ expanding regulatory calendar also comes with trial and approval risk that investors should not overlook.Ionis Pharmaceuticals’ shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.
Exploring Other Perspectives 
IONS 1-Year Stock Price Chart
Three Simply Wall St Community fair value estimates for Ionis span roughly US$80 to a very large figure, reflecting sharply different views on upside. Set this against the recent Phase 3 failure and intensified scrutiny of Ionis’ pipeline, and it becomes clear why taking time to compare multiple viewpoints on the company’s future performance matters.
Explore 3 other fair value estimates on Ionis Pharmaceuticals – why the stock might be worth just $79.71!
Form Your Own Verdict
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Ionis Pharmaceuticals’ overall financial health at a glance.
Curious About Other Options?
Our daily scans reveal stocks with breakout potential. Don’t miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IONS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com